Summary
Large neutral amino acids (LNAA) have been used on a limited number of patients with phenylketonuria (PKU) with the purpose of decreasing the influx of phenylalanine (Phe) to the brain. In an open-label study using LNAA, a surprising decline of blood Phe concentration was found in patients with PKU in metabolic treatment centres in Russia, the Ukraine, and the United States. To validate the data obtained from this trial, a short-term double-blind placebo control study was done using LNAA in patients with PKU, with the participation of three additional metabolic centres – Milan, Padua and Rio de Janeiro. The results of the short trial showed significant lowering of blood Phe concentration by an average of 39% from baseline. The data from the double-blind placebo control are encouraging, establishing proof of principle of the role of orally administered LNAA in lowering blood Phe concentrations in patients with PKU. Long-term studies will be needed to validate the acceptability, efficacy and safety of such treatment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- BBB:
-
blood–brain barrier
- LNAA:
-
large neutral amino acids
- Phe:
-
phenylalanine
- PKU:
-
phenylketonuria
- VIL:
-
valine, isoleucine and leucine
References
Azen C, Koch R, Friedman EG, et al (1991) Intellectual development in 12-year-old children treated for phenylketonuria. Am J Dis Child 145: 35–39.
Blau N, Scriver CR (1997) New approaches to treat PKU: How far are we? Mol Genet Metab 81: 1–2.
Blau N, Trefz F (2002) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency: possible regulation of gene expression in a patient with the homozygous L48S mutation. Mol Genet Metab 75: 186–187.
Bickel H, Gernrard J, Hickmans EM (1953) Influence of phenylalanine intake on phenylketonuria. Lancet 2: 812–813.
Burgard P, Rey F, Rupp A, Abadie V, Rey J (1997) Neuropsychologic functions of early treated patients with phenylketonuria, on and off diet: results of a cross-national and cross-sectional study. Pediatr Res 41: 368–374.
Choi TB, Pardridge WM (1986) Phenylalanine transport at the human blood–brain barrier. J Biol Chem 261: 6536–6541.
Diamond A (2001) A model system for studying the role of dopamine in the prefrontal cortex during early development in humans: early and continuously treated phenylketonuria. In Nelson CA, Luciana M, eds. Handbook of Cognitive Neuroscience. Cambridge, MA: MIT Press, 433–472.
Dotremont H, Francois B, Diels M, Gillis P (1995) Nutritional value of essential amino acids in the treatment of adults with phenylketonuria. J Inherit Metab Dis 18: 127–130.
Erlandsen H, Pey AL, Gamez A, et al (2004) Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci USA 101(48): 16903–16908.
Fisch RO, Chang PN, Weisberg S, Guldberg P, Guttler F, Tsai MY (1995) Phenylketonuria patients decades after diet. J Inherit Metab Dis 18: 426–427.
Fisch R, Matalon R, Weisberg S, Michals K (1997) Phenylketonuria: current dietary treatment practices in the United States and Canada. Am J Coll Nutr 16: 147–151.
Folling A (1934) Uber Ausscheidung von Phenylbrenztraubensaure in den Harn als Stoffwechselanomalie in Verbindung mit Imbezillitat. Hoppe-Seylers Z Physiol Chem 277: 169.
Griffiths P, Paterson L, Harvie A (1995) Neuropsychological effects of subsequent exposure to phenylalanine in adolescents and young adults with early-treated phenylketonuria. J Intellec Dis Res 39: 365–372.
Gleason LA, Michals K, Matalon R, Langenberg P, Kamath S (1992) A treatment program for adolescents with phenylketonuria. Clin Pediatr 6: 331–335.
Hargreaves KM, Pardridge WM (1988) Neutral amino acid transport at the human blood–brain barrier. J Biol Chem 263(19): 392–397.
Hidalgo IJ, Borchardt RT (1990) Transport of a large neutral amino acid (phenylalanine) in a human intestinal epithelial cell line: Caco-2. Biochim Biophys Acta 1028(1): 25–30.
Jervis GA (1953) Phenylpyruvic oligophrenia: deficiency of phenylalanine oxidising system. Proc Soc Exp Biol Med 82: 514–515.
Kaufman S (1971) The phenylalanine hydroxylating system from mammalian liver. Adv Enzymol 35: 245–319.
Kure S, Hou DC, Ohura T, et al (1999) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency: a novel clinical entity. J Pediatr 135: 375–378.
Larsen PR, Ross JE, Tapley DF (1964) Transport of neutral, dibasic and N-methyl substituted amino acids by rat intestine. Biochim Biophys Acta 88: 570–577.
Lassker U, Zschocke J, Blau N, Santer R (2002) Tetrahydrobiopterin responsiveness in phenylketonuria. Two new cases and a review of molecular genetic findings. J Inherit Metab Dis 25: 65.
Lindner M, Hass D, Zschocke J, Burgard P (2003a) Tetrahydrobiopterin responsiveness in phenylketonuria differs between patients with the same genotype. Mol Genet Metab 73: 104–106.
Lindner M, Steinfeld R, Burgard P, Schulze A, Mayatepek E, Zschocke J (2003b) Tetrahydrobiopterin sensitivity in German patients with mild phenylalanine hydroxylase deficiency. Hum Mutat 21: 400.
Lou H, Guttler F, Lykkelund C, Bruhn P, Niewieser A (1985) A decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents. Eur J Pediatr 144: 17–20.
Matalon R, Koch R, Michals-Matalon K, Moseley K, Stevens RC (2002) Tetrahydrobiopterin-responsive phenylalanine hydroxylase mutation. J Inherit Metab Dis 25(Supplement): 23.
Matalon R, Surendran S, Michals-Matalon K, et al. (2003) Future role of large neutral amino acids in transport of phenylalanine into the brain. Pediatrics 122: 1570–1574.
Matalon R, Koch R, Michals-Matalon K, et al (2004) Biopterin responsive phenylalanine hydroxylase deficiency. Genet Med 6(1): 27–32.
Matalon R, Michals-Matalon K, Bhatia G, et al (2006) Large neutral amino acids in the treatment of phenylketonuria (PKU) J Inherit Metab Dis 29: 732–738.
MRC Working Party on Phenylketonuria (1993) Recommendation on the dietary management of phenylketonuria. Arch Dis Child 68: 426–427.
Muntau AC, Roschinger W, Habich M, et al (2002) Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med 347: 2122–2132.
Michals K, Dominick M, Schuett V, Brown E, Matalon R (1985) Return to diet therapy in patients with phenylketonuria. J Pediatr 106: 933–936.
Michals K, Azen C, Acosta PB, Koch R, Matalon R (1988) Blood phenylalanine and intelligence of ten-year-old children with phenylketonuria in the national collaborative study. J Am Diet Assoc 88: 1226–1229.
NIH Consensus Report on Phenylketonuria (2001) Phenylketonuria: screening and management of PKU. US Department of Health and Human Services, Public Health Services, National Institutes of Health, National Institute of Child Health and Human Services.
Oldendorf WH, Szabo J (1976) Amino acid assignment to one of three blood–brain barrier amino acid carriers. Am J Physiol 230: 94–98.
Pardridge WM (1977) Kinetics of competitive inhibition of neutral amino acid transport across the blood–brain barrier. J Neurochem 28: 103–108.
Pardridge WM (1982) Blood–brain barrier amino-acid transport: clinical implications. In: Cockburn F, Gitzelmenn R, eds. Inborn Errors of Metabolism in Humans. Lancaster, UK: MTP Press, 87–99.
Pardridge WM, Oldendrof WH (1975) Kinetic analysis of blood–brain barrier transport of amino acids. Biochim Biophys Acta 401: 128–136.
Pietz J, Landwehr R, Kutscha A, Schmidt H, de Sonneville L, Trefz FK (1995) Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria. J Pediatr 127: 936–943.
Pietz J, Dunckelmann R, Rupp A, et al (1998) Neurological outcome in adult patients with early-treated phenylketonuria. Eur J Pediatr 157: 824–830.
Ris MD, Williams SE, Hunt MM, Berry HK, Leslie N (1994) Early-treated phenylketonuria: adult neuropsychological outcome. J Pediatr 124: 388–392.
SAS Institute (2004) SAS/STAT 9.1 User’s Guide. Cary, NC: SAS Institute Inc.
Scriver CR, Kaufman S (2001) Hyperphenylalaninemias: phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 1667–1724.
Schmidt E, Rupp A, Burgard P, Pietz J, Weglage J, de Sonneville L (1994) Sustained attention in adult phenylketonuria: the influence of the concurrent phenylalanine blood-level. J Clin Exp Neuropsychol 16: 681–688.
Seashore MR, Friedman E, Novelly RA, Bapat V (1985) Loss of intellectual function in children with phenylketonuria after relaxation of dietary phenylalanine restriction. Pediatrics 75: 226–232.
Smith I, Lobascher M, Stevenson J, et al (1978) Effect of stopping the low phenylalanine diet on the intellectual progress of children with phenylketonuria. Br Med J 2: 723–726.
Smith I, Beasley MG, Ades AE (1991) Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria. Arch Dis Child 66(3): 311–316.
Spaapen LJM, Bakker JA, Velter C, et al (2000) Tetrahydrobiopterin-responsive hyperphenylalaninemia (HPA) in Dutch neonates. J Inherit Metab Dis 23(Supplement 1): 45.
Thompson AJ, Smith IL, Brenton D, et al (1990) Neurological deterioration in young adults with phenylketonuria. Lancet 336: 602–605.
Thompson AJ, Tillotson A, Smith I, Kendall B, Moore SG, Brenton DP (1994) Brain MRI changes in phenylketonuria. Associations with dietary status. Brain 344: 87–90.
Trefz F, Blau N, Aulehla-Scholz C, Korall H, Frauendienst-Egger G (2000) Treatment of mild phenylaketonuria (PKU) by tetrahydrobiopterin (BH4) J Inherit Metab Dis 23(Supplement 1): 47.
Trefz F, Aulehla-Scholz C, Blau N (2001) Successful treatment of phenylketonuria with tetrahydrobiopterin. Eur J Pediatr 160: 315.
Walter JH, White FJ, Hall SK, et al (2002) How practical are recommendations for dietary control in phenylketonuria? Lancet 360: 55–57.
Weglage J, Grenzebach M, Teeffelen-Heithoff T, et al (2002) Tetrahydrobiopterin responsiveness in a large series of phenylketonuria patients. J Inherit Metab Dis 25: 321–322.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Verena Peters
Competing interests: None declared
References to electronic databases: Phenylketonuria (PKU; OMIM 261600)
Rights and permissions
About this article
Cite this article
Matalon, R., Michals-Matalon, K., Bhatia, G. et al. Double blind placebo control trial of large neutral amino acids in treatment of PKU: Effect on blood phenylalanine. J Inherit Metab Dis 30, 153–158 (2007). https://doi.org/10.1007/s10545-007-0556-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-007-0556-4